Strategic partnerships Mestag has active and past collaborations with MSD/Janssen/JJDC, Johnson & Johnson, and license licenses; leverage these ties to explore co-development or expansion opportunities, cross-funding on additional inflammatory disease and cancer targets, and joint research programs.

Lead program readiness Lead program MST-0312 is advancing toward mid-2026 clinical development with significant investor backing; pursue discussions around compassionate use, investigator-initiated trials, or advisory roles to accelerate validation and potential in-licensing or milestone-based partnerships.

Financing signals Recent $40M financing from top life-science investors indicates strong growth trajectory; approach to explore strategic co-investment, bridge financing for expansion of additional targets, or portfolio-level licensing conversations with larger biotech/pharma players.

Clinical and academic engagement Active participation in high-profile events (AACR, Keystone Symposia) and targeted LTBR agonist data generation; leverage these platforms for joint publications, sponsored clinical initiatives, and opportunities to connect with potential CROs, contract manufacturers, or translational partners.

Therapeutic focus fit Specialization in fibroblast-immune interactions for inflammatory disease and cancer aligns with a broad market need and existing pharma interest in targeted immunomodulatory therapies; position for in-licensing discussions, target discovery collaborations, and platform-wide partnerships with companies seeking novel targets in the fibrotic/immune axis.